Ashritha R. Chalamalla
Role not yet determined Is this you? Add your title
Also affiliated: University of Alabama at Birmingham (2024–2026); UAB Medicine (2024–2025); Arkansas Children's Research Institute (2024–2026)
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Ashritha R. Chalamalla's research focuses on the pharmacokinetics and clinical response of CFTR modulators in individuals with cystic fibrosis. Her work investigates how drug concentrations, dietary patterns, and concurrent medications impact treatment efficacy and patient outcomes. Recent publications examine the pharmacokinetic variability of different CFTR modulator regimens, the relationship between modulator concentrations and clinical response, and the feasibility of assessing dietary composition alongside these therapies. Chalamalla also explores the use of machine learning approaches for predicting average drug concentrations based on sparse sampling data. Her collaborations include extensive work with Jennifer S. Guimbellot and Saly Abouelenein at the University of Arkansas for Medical Sciences, with whom she has co-authored numerous publications.
Metrics
- h-index: 3
- Publications: 19
- Citations: 21
Selected Publications
-
Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis (2026)
-
Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy (2026)
-
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025)
Collaboration Network
Top Collaborators
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
Similar Researchers
Based on overlapping research topics